What is the primary purpose of this 10-Q filing?

This 10-Q filing is a quarterly report that provides the Securities and Exchange Commission (SEC) and the public with a regular update on Abbott Laboratories' financial performance and operational status for the period ending September 29, 1996. It allows investors to track the company's progress between annual reports.

Where can I find specific financial data like revenue and net income in this filing?

The provided text is a directory listing of the filing's components on the SEC EDGAR system. To find specific financial data such as revenue, net income, balance sheet details, and cash flow statements, you would need to access the full text of the 10-Q report (likely a .txt or HTML file) from the SEC's EDGAR database.

What kind of qualitative information should I look for in this report?

Beyond the numbers, investors should look for the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section. This typically provides insights into the company's performance drivers, significant events, trends, risks, and management's outlook for the future, which are crucial for understanding the context of the financial results.

Does this filing mention any significant events or changes for Abbott Laboratories in Q3 1996?

The provided directory listing itself does not contain specific details about significant events or changes. Accessing the full 10-Q document would be necessary to review management's narrative and financial statements for any such disclosures, which could include product launches, regulatory updates, or strategic decisions.

ABT 10-Q Quarterly Report Q3 FY1996 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' 10-Q filing for the period ending September 29, 1996, reveals a company navigating its operational landscape. While specific financial performance figures and segmental analysis are not directly available in the provided directory listing, the filing indicates the routine submission of quarterly financial data to the SEC. Investors would typically look for details on revenue growth, profitability margins, and any significant year-over-year changes in these metrics to assess the company's financial health and trajectory. Furthermore, this filing would likely contain management's discussion and analysis of financial condition and results of operations, which would offer insights into key business drivers, strategic initiatives, and potential risks. Any disclosures regarding acquisitions, divestitures, product developments, or regulatory matters would be crucial for a comprehensive understanding of Abbott's performance and outlook during this quarter.

Key Highlights

1Quarterly Report (10-Q) filed for the period ending September 29, 1996.
2Company: Abbott Laboratories (ABT).
3Filing Date: November 12, 1996.
4The filing indicates routine submission of financial information to the SEC.
5Investors would typically analyze this report for financial performance indicators.
6Key areas of interest for investors include revenue, profitability, and operational trends.
7Discussions on business drivers, strategic initiatives, and risks are usually part of such filings.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 1996

Summary

Key Highlights

Frequently Asked Questions